MGX292 / Centessa - LARVOL DELTA

MGX292, A Novel Variant of Native Bone Morphogenetic Protein 9 (BMP9) That Lacks Osteogenic Activity, Reverses Vascular Remodelling and Pulmonary Arterial Hypertension in the Sugen-hypoxia Rat Model (ATS 2023) - "The 8-week SuHx protocol consisted of a single subcutaneous injection of SU5416 (20mg/kg) followed by 4 weeks in 10% oxygen (hypoxia), then back into room air (normoxia). MGX292 has been designed as a first-in-class non-osteogenic variant of human BMP9 that retains endothelial signaling and protective activity. Given these encouraging preclinical data, MGX292 is being developed as a potential therapeutic agent for the treatment of PAH."

Late-breaking abstract • Preclinical • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases